title: Tocilizumab and adalimumab in an 18q deletion syndrome patient with chronic arthritis.
authors: Department of Paediatrics, Akita City Hospital, Japan, Akita City, Akita, Japan.
authors: Soki
authors: S
authors: Kashima
authors: Department of Paediatrics, Akita University School of Medicine, Akita City, Akita, Japan.
authors: Satoko
authors: S
authors: Tsuchida
authors: Department of Paediatrics, Akita City Hospital, Japan, Akita City, Akita, Japan.
authors: Hiromi
authors: H
authors: Koizumi
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D002648:Child; D002872:Chromosome Deletion; D025063:Chromosome Disorders / Q000175:diagnosis / Q000235:genetics / Q000276:immunology*; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics / Q000276:immunology; D057915:Drug Substitution; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D010641:Phenotype; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab; C502936:tocilizumab